NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 59 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q2 2021. The put-call ratio across all filers is 0.89 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $790,000 | -37.1% | 372,476 | -20.2% | 0.22% | -58.2% |
Q2 2022 | $1,255,000 | -48.3% | 466,607 | -16.5% | 0.53% | +36.3% |
Q1 2022 | $2,426,000 | -55.4% | 559,019 | -46.7% | 0.39% | -80.4% |
Q4 2021 | $5,438,000 | -9.2% | 1,049,721 | +7.7% | 1.98% | +30.6% |
Q3 2021 | $5,987,000 | -34.1% | 975,000 | +8.3% | 1.51% | -53.5% |
Q2 2021 | $9,090,000 | – | 900,000 | – | 3.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
AH Equity Partners Bio II, L.L.C. | 16,298,006 | $16,298,000 | 8.49% |
Madrona Venture Group, LLC | 6,020,770 | $31,188,000 | 5.89% |
ArchPoint Investors | 1,449,551 | $7,509,000 | 2.23% |
Ally Bridge Group (NY) LLC | 1,225,060 | $6,346,000 | 2.22% |
Affinity Asset Advisors, LLC | 1,049,721 | $5,438,000 | 1.98% |
Tikvah Management LLC | 1,231,835 | $6,381,000 | 1.78% |
Bain Capital Life Sciences Investors, LLC | 2,000,000 | $10,360,000 | 0.82% |
AH Equity Partners LSV II, L.L.C. | 1,355,911 | $1,356,000 | 0.74% |
Perceptive Advisors | 18,222,302 | $94,390,000 | 0.73% |
SPHERA FUNDS MANAGEMENT LTD. | 800,000 | $4,144,000 | 0.46% |